Hidradenitis Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Funding
• Clinical Trials
• Forums

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Condition:   Hidradenitis Suppurativa (HS) Interventions:   Drug: Povorcitinib;   Drug: Placebo Sponsor:   Incyte Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2022 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Condition:   Hidradenitis Suppurativa (HS) Interventions:   Drug: Povorcitinib;   Drug: Placebo Sponsor:   Incyte Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2022 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Condition:   Hidradenitis Suppurativa (HS) Interventions:   Drug: Povorcitinib;   Drug: Placebo Sponsor:   Incyte Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2022 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Condition:   Hidradenitis Suppurativa (HS) Interventions:   Drug: Povorcitinib;   Drug: Placebo Sponsor:   Incyte Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2022 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Condition:   Hidradenitis Suppurativa (HS) Interventions:   Drug: Povorcitinib;   Drug: Placebo Sponsor:   Incyte Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2022 Category: Research Source Type: clinical trials

Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)
Condition:   Hidradenitis Suppurativa (HS) Intervention:   Drug: secukinumab Sponsor:   Novartis Pharmaceuticals Temporarily not available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2022 Category: Research Source Type: clinical trials

Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)
Condition:   Hidradenitis Suppurativa (HS) Intervention:   Drug: secukinumab Sponsor:   Novartis Pharmaceuticals Available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2022 Category: Research Source Type: clinical trials